Latest research on Desvenlafaxine

Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.

Desvenlafaxine interactions

Patients who had received treatment with Venlafaxine or DesVenlafaxine in the past; a history of personality disorder or mental retardation, substance abuse, psychotic disorders, dementia, obsessive compulsive disorder, post-traumatic stress disorder, bipolar disorder, anxiety disorder, or active suicidal tendency; other clinically important medical conditions as determined by the investigators; or any other unstable medical condition such as cardiovascular disease were excluded. [source, 2016]
The efficacy and the tolerability of Escitalopram, aSSRI and Desvenlafaxine, a non-selective SRI has been well-established. [source, 2016]
Thus, there are very limited studies available directly comparing efficacies of Escitalopram with Desvenlafaxine in treatment of major depression. [source, 2016]
Hence, a preliminary 1-year prospective randomized open label trial comparing efficacy and safety of Escitalopram with Desvenlafaxine in the treatment of major depression was undertaken. [source, 2016]
Patients meeting eligibility criteria at the screening visit were assigned randomly in 1:1 ratio to either receive Escitalopram or Desvenlafaxine. [source, 2016]
Both Escitalopram as well as Desvenlafaxine significantly (P < 0.001) reduced HAM-D, HAM-A, and CGI scores from their respective base lines [Table 2]. [source, 2016]
In the present study, there was a trend toward the higher overall response of Escitalopram in decreasing depression and anxiety than with Desvenlafaxine (F = 3.014, P = 0.057). [source, 2016]
Our results are almost in accordance to those put forth by Soares et al.,[14] who reported a similar reduction in depression with Escitalopram and Desvenlafaxine. [source, 2016]
No significant difference was observed between groups at continuation phase end points in the proportion of who maintained response (Desvenlafaxine, 82%; Escitalopram, 80%, P = 0.70). [source, 2016]
Limited studies have directly compared the efficacy of Escitalopram with Desvenlafaxine in treatment of major depression, otherwise Escitalopram has been compared with class SNRI's in other studies. [source, 2016]